Open AccessManagement of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
Author(s) -
Pak Yui Fong,
Shing Chuen Chow,
Bernard Ming Hong Kwong,
Charlene Cheuk Lam Lau,
Christy Yik Ching Lau,
Athena Hoi Ting Lee,
Ha Ying Nip,
CheukYin Wong,
Benedict Tsz Hin Yan,
Ho Yin Chung
Publication year - 2020
Publication title -
journal of clinical rheumatology and immunology
Language(s) - English
Resource type - Journals
eISSN - 2661-3425
pISSN - 2661-3417
DOI - 10.1142/s2661341720300013
Subject(s) - medicine , polymyalgia rheumatica , eosinophilic fasciitis , adverse effect , immunology , rheumatology , rheumatoid arthritis , immune system , ipilimumab , arthritis , pembrolizumab , dermatology , immunotherapy , giant cell arteritis , disease , vasculitis , eosinophilia
Immune checkpoint inhibitors (ICIs) have forged a new direction for the treatment of cancer. However, ICIs – programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors – are also known to cause immune-related adverse events (irAEs). Rheumatological adverse events are uncommon and often low grade, but flares of underlying rheumatological diseases may be triggered. Guidelines are available for the effective management of the rheumatological adverse events that more frequently arise from the use of ICIs, such as inflammatory arthritis, inflammatory myopathies, Sjogren syndrome, scleroderma, and polymyalgia rheumatica and eosinophilic fasciitis.